Developed in the last 15 years, a new class of sugar-lowering drugs – glucagon-like peptide-1 receptor agonists – has become one of the leaders in the treatment of type 2 diabetes mellitus, prediabetes and obesity. Numerous studies have proven the cardiovascular safety of this medicine class, their cardioprotective and nephroprotective effects. That served as the basis for making changes to clinical recommendations on the management of patients with type 2 diabetes mellitus.

1. Algoritmy specializirovannoj medicinskoj pomoshchi bol‘nym saharnym diabetom / Pod redakciej I. I. Dedova, M. V. Shestakovoj, A. Yu. Majorova. – 9-j vypusk (dopolnennyj). – M.; 2019.

2. Bova A. A., Gromova Yu. M., Rudoj A. S., Kurlyanskaya E. K. Kardiovaskulyarnye riski u pacientov s saharnym diabetom: Rukovodstvo dlya vrachej / A. A. Bova [i dr.]. – Minsk: NiktaGrafiksPlyus. – 2020. – 188 s.

3. Galstyan G. R., Karataeva E. A., Yudovich E. A. Evolyuciya agonistov receptorov glyukagonopodobnogo peptida-1 v terapii saharnogo diabeta 2 tipa // Saharnyj diabet. 2017;20(4):286-298.

4. Mkrtumyan A. M., Markova T. N., Mishchenko N. K. Analiz serdechno-sosudistoj bezopasnosti sovremennyh saharosnizhayushchih preparatov / Kardiologiya. – M: 2019; 7 (59): 76-83.

5. Saharnyj diabet i ishemicheskaya bolezn‘ serdca – opasnyj koktejl‘. A. Yu. Fedorov / Sovremennaya Kardiologiya: OOO «Izdatel‘skij dom «ABV-press», № 3 (13), 2019. – S. 4–5.

6. Tyurenkov I. N., Bakulin D. A., D. V. Kurkin, E. V. Volotova Kardiovaskulyarnye effekty inkretinomimetikov i ih terapevticheskij potencial / VESTNIK RAMN /2017/ 72 (1). – S. 66–75.

7. FDA. Guidance for industry diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring: FDA. 2008; 1-8

8. IDF Diabetes Atlas 8th edition 2017

9. Standards of medical care in diabetes – 2020: American Diabetes Association / Diabetes Care (2020); 43 (Suppl. 1): 224 s.

10. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD / European Heart Journal (2019) 00, 1-69.